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Abstract.  Treatment of platelets with thrombin was 
shown previously to induce rapid changes in tyrosine 
phosphorylation of several platelet proteins. In this re- 
port, we demonstrate that a variety of agonists which 
induce platelet aggregation also stimulate tyrosine 
phosphorylation of three proteins with apparent molec- 
ular masses of 84, 95,  and 97 kD.  Since platelet 
aggregation requires the agonist-induced activation of 
an integrin receptor (GP IIb-IRa) as well as the bind- 
ing of fibrinogen to this receptor, we examined the 
relationship between tyrosine phosphorylation and the 
function of GP lib-Ilia.  When platelets were examined 
under conditions that either precluded the activation of 
GP lib-iRa (prior disruption of the complex by EGTA 
at 37°C) or the binding of fibrinogen (addition of 
RGDS or an inhibitory rnAb), tyrosine phosphoryla- 
tion of the 84-,  95-, and 97-kD proteins was not ob- 
served. However, although both GP lib-iRa activation 
and fibrinogen binding were necessary for tyrosine 
phosphorylation, they were not sufficient since phos- 
phorylation was observed only under conditions in 
which the activated platelets were stirred and allowed 
to aggregate. In contrast, tyrosine phosphorylation was 
not dependent on another major platelet response, dense 
granule secretion. Furthermore, granule secretion did 
not require tyrosine phosphorylation of this set of pro- 
teins. These experiments demonstrate that agonist- 
induced tyrosine phosphorylation is linked to the pro- 
cess of GP l/b-IRa-mediated platelet aggregation. 
Thus, tyrosine phosphorylation may be required for 
events associated with platelet aggregation or for 
events that follow aggregation. 
p 
LATELETS are an excellent model system in which to 
study the mechanisms of signal transduction.  Physio- 
logical agonists elicit a variety Of cellular responses 
including shape change, aggregation, granule secretion, and 
generation of membrane procoagulant activity. The trans- 
duction mechanisms that lead to these platelet responses in- 
elude activation  of guanine nueleotide-binding proteins, 
hydrolysis of membrane phospholipids,  release and metabo- 
lism of arachidonic acid, influx and mobilization of calcium, 
and stimulation  of protein phosphorylation (Siess,  1989; 
Brass et ai.,  1990). 
The role of protein phosphorylation in platelet responses 
has been the subject of intensive study (Kroll and Schafer, 
1989; Siess, 1989). Many of the phosphorylation events ob- 
served upon platelet stimulation have been attributed to the 
actions of protein kinase C and myosin light chain kinase, 
both of which are serine/threonine-specific  protein kinases. 
Recently, several tyrosine-speeific protein kinases have been 
detected in platelets.  These include the cellular src gene 
product (Golden et al., 1986; Varshney et al., 1986; Presek 
et al., 1988; Rendu et al., 1989), the ceUularfyn gene prod- 
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uct (Horak et al.,  1989), and several unidentified  kinases 
(Nakamura et al., 1985, 1988). Moreover, a number of pro- 
teins are phosphorylated  on tyrosine residues after platelet 
activation by thrombin and other platelet agonists (Ishihara 
et al.,  1985; Ferrell and Martin,  1988, 1989; Golden and 
Brugge, 1989; Nakamura and Yamarnura, 1989). The iden- 
tity of the protein-tyrosine kinases and their substrates and 
the precise role of tyrosine pbosphorylation  during platelet 
activation remain to be determined. Recently, Ferrell and 
Martin have shown that thrombin-induced tyrosine phos- 
phorylation of several platelet proteins appears  to require 
ligand binding to the platelet membrane glycoprotein (GP) ~ 
IIb-llla complex (Ferrell and Martin, 1989), a member of 
the integrin family  of  adhesion receptors (Pytela et al., 1986; 
Hynes, 1987). 
GP Hb-iRa plays a critical role in platelet aggregation, a 
process that requires the agonist-induced binding of fibrino- 
gen to GP IIb-iRa (Bennett and Vilaire,  1979; Plow and 
Ginsberg,  1989). Agonists activate GP Hb-I~a, presumably 
by inducing a eonformational change that exposes a binding 
site  for fibrinogen,  thus enabling  fibrinogen  to bind in a 
calcium-dependent manner (Shattil  et al.,  1985a,  1986). 
1. Abbreviations used in this paper: GE glycoprotein. 
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that the cells physically  interact. Several lines of evidence 
suggest that fibrinogen-mediated aggregation is coupled to 
other platelet response pathways. First, the activated form of 
GP  Ilb-IIIa  has  been  implicated  in  platelet  Na+/H  + ex- 
change and in activation of phospholipase A2 (Swear et al., 
1985, 1986; Banga et al., 1986). Second, when platelets are 
stimulated by so-called "weak" agonists such as ADP or epi- 
nephrine,  platelet  aggregation is required for arachidonic 
acid  metabolism,  thromboxane A2  synthesis,  and granule 
secretion (Huang and Detwiler,  1986).  In contrast, "strong" 
agonists, such as thrombin or collagen can induce thrombox- 
ane  A2  synthesis  and  granule  secretion  independent  of 
platelet aggregation. However, even in the case of thrombin 
or collagen,  aggregation  is required to promote association 
of GP Hb-IHa with the Triton-insoluble  membrane cyto- 
skeleton (Phillips  et al.,  1980; Fox,  1987) and to activate 
calcium-dependent proteases (callpalns) within the cell (Fox, 
1987). 
Given the presence of multiple-protein tyrosine kinases in 
platelets, the rapid induction of tyrosine phosphorylation af- 
ter platelet activation, and the central role of GP Hb-iRa in 
platelet function, we sought to further define the relationship 
between GP I/b-IHa and tyrosine phosphorylation.  GP lib- 
IRa activation was monitored both by aggregometry and by 
a sensitive flow cytometric technique that measures the bind- 
ing of an mAb specific for the activated conformation of GP 
lib-IRa.  Tyrosine phosphorylation was studied using immu- 
noblots  probed  with  an  affinity-purified  polyclonal  an- 
tiphosphotyrosine antibody. We demonstrate here that acti- 
vation of GP lib-IRa and fibrinogen binding to GP fib-IRa 
are required, but not sufficient, for tyrosine phosphorylation 
of three specific  platelet proteins with apparent molecular 
masses of 84, 95, and 97 kD. The phosphorylation of these 
proteins also requires platelet aggregation. 
Materials and Methods 
Isolation of  Platelets 
Venous blood was  collected from healthy drug-free volunteers  and an- 
ticoagulated  with 0.01 vol 40% sodium citrate or 0.15 vol NIH Formula A 
acid-citrate-dextrose  solution.  Platelet isolation was carried out at room 
temperature.  Platelet-rich  plasma was obtained by centrifilgation  of whole 
blood at  180 g  for 20 rain.  After addition of  1 /tM prostaglandin Et 
(PGE1), platelets were separated from plasma by gel-filtration  (Tangen et 
al.,  1971) over a  Sepharose-2B  column equilibrated with an incubation 
buffer containing 137 mM NaC1, 2.7 mM KC1, 1 mM MgC12, 5.6 mM gin- 
cose,  1 mg/ml BSA, 3.3 mM NaH2PO4, and 20 mM Hepes (Sigma Chemi- 
cal Co., St. Louis, MO), pH 7.4. Gel-filtered platelets were counted in an 
electronic particle counter (Coulter Electronics,  Hialeah, FL) and adjusted 
to a concentration of 1-3  x  l0  s platelets/ml with incubation buffer. 
Activation of Gel-filtered Platelets 
Immediately  after gel filtration,  200 ~M CaC12 was added to the platelet 
suspension and platelets  were stimulated for 1 rain at 37°C  with bovine 
c~-thrombin (1  U/mi; Chrono-Log, Havertown,  PAL collagen  (5 /zg/mi; 
Chrono-Log), ADP or a combination  of  ADP and epinephrine (10 ~tM each; 
Chrono-Log), phorbol 12-myristate  13-acetate (100 nM; Sigma Chemical 
Co.), A23187 (1 ;tM; Sigma Chemical Co.), or mastoparan (50 ttM; Sigma 
Chemical Co.  or an HPLC-purified preparation; gift from Elliott Boss 
[University of Texas Southwestern  Medical Center,  Dallas,  TX]; Higashi- 
jima et al.,  1988).  In the case of ADP and epinephrine, purified human 
fibrinogen (50/~g/ml) was also added to support platelet aggregation when 
the suspensions were stirred (Bennett and Vilaire,  1979). In the case of the 
other agonists, sufficient fibrinogen was released from platelet alpha-gran- 
ules to support the aggregation of stirred platelets.  As specified in each ex- 
periment, incubations were carried out either without stirring (to prevent 
aggregation) or in the presence of a magnetic stir bar rotated at 1,000 rpm. 
In  some experiments,  the binding of fibrinogen to GP Iro-Illa was 
prevented by incubating the gel-filtered platelets with either the tetrapeptide 
RGDS (500/~M; Sigma Chemical Co. or Peninsula Laboratories, Belmont, 
CA),  10 mM EDTA, or the anti-GP Ilb-IIIa mAb; A2A9 (50-100 ;~g/mi) 
(Bennett et al., 1983) for 2 min before the addition of an ngonist. In other 
experiments,  platelets in plasma were preincubated with 10 mM EGTA for 
90 rain at either 20  ° or 37°C,  and then equimolar CaC12 was added back 
just before gel filtration.  EGTA treatment at 37°C disrupts the integrity of 
the GP Hb-IHa complex and renders it incompetent to bind fibrinogen or 
support aggregation  even after the addition of equlmolar CaCl2 (Brass et 
al., 1985; Fitzgerald and Phillips, 1985; Shattil et al., 1985b; Pidard et al., 
1986). As a control, some platelets were preincuhatnd with EGTA at 20°C, 
a condition that does not disrupt GP Hb-Ilga (Shatfil et al., 1985b; Pidard 
et al., 1986). In some experiments, the blood donor ingested 650 mg of aspi- 
rin 24 and 2 h before venepuncture to inhibit arachidonic acid metabolism 
through the cyclooxygenase pathway (Burch et al.,  1978). To insure virtu- 
ally complete inhibition of cyclooxygenase,  experiments with these gel- 
filtered platelets were carried out in the presence of 10 p.M indomethacin 
(Sigma Chemical Co.). In some experiments, the gel-filtered platelets were 
incubated with the cell-permeable calpain inhibitor E64d (100  mg/mi) 
(McGowen et al., 1989) for 5 min at 250C before thrombin  stimulation. Cal- 
pain inhibition  was assayed by visualization of the total protein profile after 
staining the gels with Coomassie blue. 
Measurement of Platelet Aggregation and Dense 
Granule Secretion 
Platelet aggregation  and secretion of dense granule ATP were monitored 
using a  single channel lumi-aggregometer (model  400-VS;  Chrono-Log) 
(Charo et al., 1977; Feinman et al., 1977). All samples were stirred for one 
minute unless otherwise stated. The extent of platelet aggregation  in each 
sample was arbitrarily expressed relative to the aggregation of platelets si- 
muhaneously treated with 1 U/mi thrombin. For platelet samples in which 
no aggregation was apparent in the lumi-aggregometer,  a small aliquot was 
examined by phase-contrast microscopy  to determine the extent of forma- 
tion of  very small platelet aggregates (ranging from doublets to aggregates of 
25-50 platelets).  Platelet ATP secretion was quantitated by arbitrarily set- 
tint the luminescence of  untreated platelet suspensions at 0 % and thrombin- 
treated platelet suspensions at 100%. 
Measurement of GP lib-Ilia Activation and Platelet 
Alpha-Granule Secretion 
Five murine mAbs were used in these studies. The antibody PACI is specific 
for the activated form of GP IFo-I~ and binds to a fibrinogen binding site 
on GP Hb-HIa (Shattil et al.,  1985a; Tanb et al.,  1989). Antibody A2A9 
binds to both the non-activated  and activated forms of  GP Hb-HIa and there- 
fore was used to quantitate total surface-expressed  GP Ilb-nh (Bennett et 
al.,  1983). BIB5 is an antibody specific for OP Ilb and SSA6 an antibody 
specific  for GF HIa (Silver et al.,  1987).  Antibody S12, specific for the 
platelet alpha-granule membrane protein, GMP-140, was a gift from Dr. 
Rodger  P. McEver (Oklahoma Medical Research Foundation,  Oklahoma 
City, OK). This antibody binds selectively to platelets that have undergone 
alpha-granule secretion (McEver and Martin, 1984).  All antibodies were 
directly conjugated with FITC to a final flnorescein/protein  ratio of 2.5-4.0 
(Shattil et al.,  1987). 
Antibody binding to platelets was assessed by flow cytometry.  Unstirred 
gel-filtered platelets were first incubated for 1 rain at 37°C in the presence 
or absence of a platelet ngonist.  Then, aliquots  (1  x  106 cells) were in- 
cubated an additional 10 min at 22°C in a total volume of 50/~1 with a 
saturating concentration of each of the FITC-labeled  antibodies (Abrams et 
al., 1990). After dilution of each sample to 500 ~1 with PBS, platelets were 
analyzed in a FACStar (Bectun-Dicklnson Co., Oxnard, CA) flow cytome- 
ter as described previously (Shattil et al., 1987; Abrams et el., 1990). Anti- 
body binding was expressed  in arbitrary fluorescence  units as the mean 
fluorescence  intensity of 10,000 platelets.  This value for antibody binding 
is directly proportional to the number of antibody molecules bound per 
platelet (Shattii et al.,  1987). 
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phorylation of platelet proteins. (a) As de- 
scribed in Materials and Methods,  stirred 
gel-filtered platelets were treated with mas- 
toparan (50 ttM;  lane 1), collagen (5  ~g/ 
ml;  lane  2),  no  agonist  (lane  3),  ADP 
(10 t~M; lane 4), ADP plus epinephrine (10 
/zM each; lane 5), and thrombin (1  U/ml; 
lane 6). Platelets were then solubilized with 
SDS,  subjected to SDS-PAGE,  and trans- 
ferred  to  nitrocellulose  filter  paper.  The 
immunoblots  were  incubated  with  anti- 
phosphotyrosine antibodies. The values be- 
low the immunoblot represent percent ag- 
gregation  and  ATP  secretion  relative  to 
the thrombin-treated sample. Thus, values 
>100%  indicate  that  a  particular  sample 
aggregated or secreted to a  greater extent 
than  the  thrombin-treated  sample.  The 
value  of 0%  indicates  that  there  was  no 
aggregation or ATP  secretion detected  as 
assessed  by  the  lumi-aggregometer.  The 
aggregation  and  secretion  data  are  ex- 
pressed  relative  to  the  thrombin-treated 
sample, which was arbitrarily used as a ref- 
erence index for the induction of tyrosine 
phosphorylation.  (b)  Gel-filtered platelets 
treated with thrombin (1 U/ml; lane 1 ), no 
agonist (lane 2), forskolin (50 ttg/ml; lane 
3),  and  forskolin  and  thrombin  (lane  4) 
were  prepared  and  immunoblotted  as 
above. The numbers below the immunoblot 
represent  aggregation  and  ATP  secretion 
relative to the thrombin-treated sample. 
Identification of  Phosphotyrosine-containing Platelet 
Proteins by lmmunoblotting 
After activation of gel-filtered platelets for  1 min at 37"C as described 
above, the cells were sedimented for 4 s at 12,000 g in a microcentrifuge, 
solubilized in lysis buffer (2 % SDS, 0.39[ 2-mereaptoethanol, 66 mM Tris- 
HC1, pH 7.5, 10 mM EI3q'A)  and heated at 95"C for 10 min. Immunoblot 
assays  were performed as described (Yonemoto  et al., 1987). The immuno- 
blots were incubated with an  afffinity-purified  rabbit antibody to phos- 
photyrosine (lot 903; a gift from Dr. Jean Wang [University of California, 
San Diego]). This antibody has been shown to be specific for phosphotyro- 
sine residues (Wang, 1985; Morla and Wang, 1986). The binding of this 
antibody was detected using 125I-labeled  donkey anti-rabbit immunoglobu- 
lins (Amersham Corp., Arlington Heights, IL). 125I-labeled  protein bands 
were quantitated by densitometric scanning of the autoradiograms with a 
computing densitometer (Molecular Dynamics, Sunnyvale, CA). 
Results 
Effect of  Platelet Activation on lyrosine 
Phosphorylation of  Platelet Proteins 
Fig.  1 a  shows an autoradiographic  profile of platelet pro- 
teins phosphorylated on tyrosine residues 1 rain after the ad- 
dition  of agonists  to  a  suspension  of gel-filtered  platelets 
stirred at 370C. Strong physiological agonists such as throm- 
bin or collagen reproducibly induced the phosphorylation of 
three proteins with apparent molecular masses of 84, 95, and 
97 kD. Weak agonists such as ADP, or ADP in combination 
with epinephrine,  also evoked this response in stirred plate- 
lets provided that fibrinogen (50 t~g/ml) had been added to 
the incubation medium. This pattern of phosphorylation was 
also  observed  when  stirred  platelets  were  incubated  with 
agonists that circumvent the normal receptor-mediated path- 
ways of cell  activation:  mastoparan,  a  peptide  from wasp 
venom that directly activates G proteins, (Hirai et al.,  1979); 
(Fig.  1  a)  and  phorbol  12-myristate  13-acetate,  which 
directly activates protein kinase C  (Nishiznka,  1986);  data 
previously  shown in Golden and Brugge,  1989.  Forskolin, 
an inhibitor of platelet activation that acts by raising the in- 
tracellular concentration  of cAMP (Feinstein  et al.,  1983), 
prevented the changes in tyrosine phosphorylation  induced 
by thrombin (Fig.  1 b) and collagen (data not shown).  Thus, 
it appears that an identical set of proteins is phosphorylated 
on tyrosine  residues  in stirred platelets within  a  minute of 
stimulation  by a  variety of agonists.  This observation  sug- 
gests that these phosphorylation  events are linked  to some 
common platelet activation process and not coupled  solely 
to a  single agonist receptor. 
In the experiments shown in Fig.  1, the platelets were acti- 
vated under conditions in which both aggregation and secre- 
tion occurred.  Specifically, the platelets were stirred in the 
presence of fibrinogen and calcium.  For ADP and epineph- 
rine treatment, fibrinogen had been added to the platelet sus- 
pension.  For  the  other  agonists,  sufficient  fibrinogen  was 
released  from  platelet  alpha-granules  to  support  aggrega- 
tion. Indeed, platelet aggregation, ATP secretion from plate- 
let dense granules  (Fig.  1),  and alpha-granule  secretion (as 
measured by platelet binding of the anti-GMP-140 antibody, 
FITC-S12; data not shown) were observed in response to all 
Golden et al. Role of GP llb-llla in Tyrosine  Phosphorylation  3119 Figure 2.  Disruption of the GP fib-IRa complex inldbits agonist-induced tyrosine phosphorylation. (a) Platelet-rich plasma was treated 
without EGTA (Control; lanes 1-3), treated with 10 mM EGTA at 20°C for 90 minutes (lanes 4-6), or treated with 10 raM EGTA at 
37°C for 90 min (lanes 7-9) before the addition of equimolar calcium and gel filtration. The gel-filtered platelets were then incubated 
without agonist (lanes 1, 4, and 7), or with ADP and epinephrine (10 ~M each; lanes 2, 5, and 8), or thrombin (1 U/ml; lanes 3, 6, and 
9). Lysates were prepared and immnnoblotted as described in Fig.  1. The values below the immunoblot represent aggregation and ATP 
secretion relative to the thrombin-treated sample for the control platelets incubated without EGTA. (b) Effect of EGTA and temperature 
on agonist-induced PAC1 and S12 binding to platelets. Antibody binding to platelets was assessed by flow cytometry as described in 
Materials and Methods and expressed in arbitrary fluorescence units as the mean fluorescence intensity per platelet. The data represent 
the mean  +/-  SEM of six experiments. 
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Figure  3.  Inhibition  of  fibrinogen 
binding  and platelet aggregation  re- 
duces agonist-induced tyrosine phos- 
phorylation.  (a)  Gel-filtered  plate- 
lets were incubated  without agonist 
(lanes 1, 5,  and  9),  or with throm- 
bin  (1  U/ml;  lanes  3,  7,  and  11), 
RGDS  (500  /~M; lane  2),  RGDS 
and  thrombin  (lane  4),  10  mM 
EDTA (lane 6),  10 mM EDTA and 
thrombin  (lane  8),  antibody  A2A9 
(50/~g/ml; lane 10), or mAb A2A9 
and  thrombin  (lane  12),  and  pre- 
pared  and  immunoblotted  as  de- 
scribed in Fig.  1. The values below 
the  immunoblot represent  aggrega- 
tion and ATP secretion relative to the 
thrombin-treated  sample.  The  ATP 
secretion values in lanes 6 and 8 were 
not determined (ND) since EDTA in- 
terferes with the luciferase reaction 
in the lumi-aggregometer. (b) Effect 
of  RGDS,  EDTA,  and  A2A9  on 
thrombin-induced  PACI  and  S12 
binding to platelets. The data repre- 
sent the mean  +/-  SEM of two to 
six experiments. 
Golden et al. Role of GP llb-llla in  Tyrosine Phosphorylation  3121 sine phosphorylation of the 84-,  95-,  and 97-kD  proteins 
(Fig. 2 a, lane 8). In contrast, pretreatment of platelets with 
EGTA at 20°C, which does not disrupt the integrity of GP 
llb-HIa, did not affect  the subsequent binding of  FITC-PAC1, 
platelet aggregation, or tyrosine phosphorylation induced by 
ADP and epinephrine (Fig. 2 a, lane 5, and Fig. 2 b). 
Pretreatment of platelets  with EGTA  at  37°C  disrupts 
surface GP llb-IIIa,  but does not affect internal pools of 
GP fib-Ilia, which become surface-expressed after thrombin- 
stimulation and which support aggregation (Woods  et al., 
1986).  Consistent with this observation, we found that such 
thrombin-stimulated  platelets  bound  FITC-PAC1,  aggre- 
gated, and underwent agonist-induced tyrosine phosphoryla- 
tion, although each of these responses was only about 30 % 
the level of control platelets (Fig. 2, a  and b). 
In contrast, pretreatment with EGTA at 37°C did not ira- 
pair  thrombin-induced dense  granule  secretion  (ATP  re- 
lease) or alpha-granule secretion (FITC-S12 binding; Fig. 2 
b). Together,  these data suggest that tyrosine phosphoryla- 
tion requires a structurally intact form of GP fib-HIa that is 
capable of activation by agonists. 
Figure 4. Agonist-stimulated  platelets display minimal changes in 
tyrosine phosphorylation  unless they are stirred and aggregate. Gel- 
filtered platelets were treated with thrombin (1 U/ml; lanes 1 and 
3), 500 #M RGDS and thrombin (lanes 2 and 4), or no agonist (lane 
5). The platelets in lanes 3 and 4 were not stirred upon addition 
of agonists. All these samples were prepared and immunoblotted 
as described in Fig. 1. The values below the immunoblot represent 
aggregation and ATP secretion relative to the thrombin-treated 
sample. 
agonists tested.  These  results  suggest that tyrosine phos- 
phorylation of the 84-,  95-,  and 97-kD proteins is induced 
by some component of stimulus-response coupling that is 
linked to platelet aggregation and/or granule secretion. The 
following experiments were performed to explore the rela- 
tionship between tyrosine phosphorylation and events lead- 
ing to platelet aggregation. 
Relationship of 2)~osine Phosphoryiation  to Platelet 
Responses Mediated by GP IIb-IIIa 
The process of  platelet aggregation requires the activation of 
GP Hb-lIIa, resulting in exposure of  binding sites for fibrino- 
gen.  This  event  is  followed by  fibrinogen binding  and, 
provided that the cell suspension is stirred, platelet aggrega- 
tion. To assess whether GP lTo-rlla activation was necessary 
for  the  agonist-induced tyrosine  pbosphorylation pattern 
shown in Fig. 1, platelets in plasma were initially incubated 
with 10 mM EGTA at 37°C for 90 rain,  CaC12 (10 raM) 
was then added,  and the platelets were gel filtered.  This 
treatment results in the irreversible disruption of surface GP 
lib-Ilia and the failure of GP lib-Ilia activation by ADP and 
epinephrine  (Brass et  al.,  1985;  Fitzgerald and  Phillips, 
1985;  Shattil et al.,  1985b;  Pidard et al.,  1986).  Incuba- 
tion with EGTA at 37°C prevented ADP and epinephrine- 
induced aggregation (Fig.  2  a,  lane 8),  and inhibited the 
binding to platelets of FITC-PAC1, an mAb specific for the 
activated form of GP llb-IHa (Fig.  2 b).  It also caused a 
significant reduction in ADP and epinephrine-induced tyro- 
Figure 5.  Inhibition of platelet cyclooxygenase  does not inhibit 
agonist-induced tyrosine  phosphorylation.  Gel-filtered platelets 
isolated from donors who had ingested aspirin were incubated with 
l0 pM indomethacin to further insure complete inhibition of ara- 
chidonic acid metabolism. The platelets were then treated with 
thrombin (1 U/m]; lane I), 100 izg/rrd  antibody A2A9 and thrombin 
(lane 2), no agonist (lane 3), ADP and epinephrine (10 ~tM each; 
lane 4), or A2A9, ADP, and epinephrine (lane 5), and prepared 
and immunoblotted  as described in Fig. 1. The values  below the im- 
munoblot represent aggregation and ATP secretion relative to the 
thrombin-treated sample. In platelets from donors not treated with 
aspirin,  indomethacin did  not  cause  a  reduction in  thrombin- 
induced tyrosine phosphorylation of the 84-, 95-, and 97-kD pro- 
teins (data not shown). 
The Journal  of Cell Biology,  Volume 111, 1990  3122 Figure 6. Inhibition of platelet calpain does not inhibit agonist- 
induced tymsine phosphorylation. (a) Coomassie blue-stained gel 
of  lysates from gel-filtered  platelets that had been incubated without 
agonist (lane 1), or with thrombin (1 U/ml; lane 2), or with E64d 
(100 mg/ml) for 5 min at 25°C before thrombin addition (lane 3). 
The three anx~he,  ads at top point to talin, aetin-binding protein, 
and myosin heavy chain. The lower three arrowheads point to the 
degradation products of myosin  heavy chain (135 kD) and of actin- 
binding protein (93 kD) which are only apparent in lane 2. (b) Gel- 
filtered platelets were incubated as described in a and prepared and 
immunoblotted as described in Fig. 1. 
Since activation of GP Wo-IHa and fibrinogen binding to 
GP l/b-Ilia are closely related, but sequential events, we then 
asked whether tyrosine phosphorylation was dependent on 
fibrinogen binding to GP lib-Ilia. To address this question, 
platelets were stimulated with thrombin in the presence of  ei- 
ther the tetrapeptide, RGDS, the divalent cation chelator, 
EDTA, or the mAb A2A9. Each of these agents is known to 
prevent fibrinogen and PAC1 binding to activated GP llb-llla 
(Bennett and Vilaire, 1979; Bennett et al., 1983; Gartner and 
Bennett, 1985).  None of these inhibitors affected the basal 
pattern of tyrosine phosphorylation when incubated in the 
absence of agonlsts (Fig. 3 a, lanes 2, 6, and 10). However, 
each agent inhibited thrombin-induced FITC-PAC1 binding 
by 70-95% (Fig. 3 b), aggregation by >80%, and thrombin- 
induced tyrosine phosphorylation of the 84-, 95-, and 97-kD 
proteins by ,x,90% (Fig. 3 a). Similar results were obtained 
when platelets were stimulated with ADP and epinephrine 
in the presence of these inhibitors (data not shown). Control 
monoclonal antibodies specific for GP fib (B1B5) or GP Ilia 
(SSAt),  which do  not inhibit fibrinogen binding,  had no 
effect on thrombin-induced PAC1 binding, platelet aggrega- 
tion, or tyrosine phosphorylation (data not shown). 
Although  RGDS,  EDTA,  and  A2A9  severely  reduced 
platelet  aggregation  and  agonist-induced  tyrosine  phos- 
phorylation, these agents had no effect on thrombin-induced 
alpha-granule secretion (platelet binding of FITC-S12; Fig. 
3  b)  or dense granule secretion (ATP release;  Fig.  3 a). 
These data indicate that the induction of  tyrosine phosphory- 
lation requires the agonist-induced binding of fibrinogen to 
GP l/b-Ilia. They also suggest that tyrosine phosphorylation 
of this set of proteins is not required for platelet secretion in 
response to thrombin. 
In separate experiments, induction of tyrosine phosphory- 
lation was not observed when platelets were stimulated to ag- 
glutinate in the presence of  von W'dlebrand factor, ristocetin, 
and EDTA (data not shown). Under these conditions, plate- 
lets clump together in a process that requires the binding of 
von Wfllebrand factor to GP Ib and is independent of GP lib- 
Ilia (Zucker et al.,  1977). 
To examine whether platelet aggregation was required for 
tyrosine phosphorylation, platelets were activated by throm- 
bin or ADP plus epinephrine in the absence of stirring. Un- 
der these conditions, GP llb-IHa is activated and is capable 
of  binding PAC1 (see Fig. 3, a and b) and fibrinogen (Bennett 
et al.,  1979),  and aggregation is prevented. In the absence 
of stirring, platelets exhibited only a minimal level of agon- 
ist-induced tyrosine phosphorylation of the 84-, 95-, and 97- 
kD proteins when compared with stirred thrombin-treated 
platelets (Fig. 4; compare lanes I and 3). Collectively, these 
studies demonstrate that the induction of tyrosine phosphor- 
ylation requires GP l/b-IIIa activation, fibrinogen binding, 
and fibrinogen-dependent platelet aggregation. 
Relationship of 1~yrosine Phosphorylation  to Platelet 
Events Subsequent to Aggregation 
Since phosphorylation of the 84-,  95-,  and 97-kD proteins 
was inhibited under conditions that blocked the process of 
platelet aggregation, we considered the possibility that acti- 
vation of tyrosine phosphorylation was  induced by  some 
platelet response that is dependent upon platelet aggregation. 
Although the events that follow platelet aggregation are not 
completely  understood,  three  such  responses  have  been 
clearly  identified:  (a)  conversion  of arachidonic  acid  to 
thromboxane A2, (b)  granule secretion (when platelets are 
stimulated with ADP or epinephrine), and (c) activation of 
platelet calcium-dependent proteases (calpains). To examine 
whether tyrosine phosphorylation required arachidonic acid 
metabolism and granule secretion, platelets were pretreated 
with aspirin and indomethacin to  inhibit cyclooxygenase. 
Since platelet secretion by ADP and epinephrine is mediated 
by arachidonic acid metabolites, blockade of cyclooxygenase 
prevents granule secretion. Platelets treated with aspirin and 
indomethacin underwent primary wave aggregation in re- 
sponse to ADP and epinephrine when stirred in the presence 
of fibrinogen. Under these conditions, dense granule secre- 
tion (ATP release) was completely inhibited (Fig. 5). Aspirin 
and indomethacin did not prevent the tyrosine phosphoryla- 
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Mediated by GP lib-Ilia 
Cellular response 
Playlet treatment  Ligand 
binding to  84-, 95-, 97-kD 
Agonist  Inhibitor  Stir  GP nb-IlIa*  Aggregation  Secretion  phosphorylation 
None  None  Yes or No  -*  -  -  - 
Thrombin  None  No  +  -  +  - 
Thrombin  None  Yes  +  +  +  + 
RGDS 
Thrombin  or A2A9  Yes  -  -  +  - 
or EDTA 
Thrombin  Aspirin  Yes  +  +  +  + 
Thrombin  Forskolin  Yes  .... 
ADP/Epi/Fibrinogen  None  No  +  -  -  - 
ADPIEpilFibrinogen  None  Yes  +  +  +  + 
RGDS 
ADP/Epi/Fibrinogen  or A2A9  Yes  .... 
or EDTA 
ADP/Epi/Fibrinogen  Aspirin  Yes  +  +  -  + 
Collagen  None  Yes  +  +  +  + 
Phorbol ester  None  Yes  +  +  +  + 
Mastoparan  None  Yes  +  +  +  + 
Ristocetin/vWf  EDTA  Yes  -  Agglutination  -  - 
* Ligand  binding refers to PAC  1  or fibrinogen  binding. 
The plus symbol  refers to a cellular response 975% of maximal; the minus symbol  refers to a cellular response  ~30% of maximal. 
tion of the 84-, 95-, and 97-kD proteins induced by ADP and 
epinephrine (Fig. 5). Thus, neither arachidonic acid metabo- 
lism nor platelet dense granule secretion appear to be abso- 
lutely necessary for the induction of tyrosine phosphoryla- 
tion. The reduced level of tyrosine phosphorylation in ADP/ 
epinephrine treated platelets (lane 4) could be a consequence 
of the inhibited secretion of factors that potentiate the aggre- 
gation response. 
Activation of platelet calpains requires platelet aggregation 
(Fox,  1987;  Weidmer et al.,  1990).  Calpain activation can 
be monitored  indirectly  on Coomassie blue-stained  SDS 
gels as a decrease in the amount of the calpain substrates, 
actin-binding protein (270 kD), talin (235 kD), and myosin 
heavy chain (200 kD) and as a concomitant increase in the 
degradation products of actin-binding protein (190 and 93 
kD), talin (190 kD), and myosin heavy chain (135 kD) (Fig. 
6 a). However, when stirred platelets were stimulated with 
thrombin in the presence of E64d, a cell permeable inhibitor 
of calpains (McGowen et al., 1989), no evidence of calcium- 
dependent protease activity could be detected  (Fig.  6  a). 
Furthermore, E64d treatment had no effect on platelet aggre- 
gation or the induction of tyrosine phosphorylation of the 
84-, 95-, and 97-kD proteins (Fig.  6  b). 
Discussion 
These studies demonstrate that activation of platelets by a va- 
riety of agonists induces tyrosine phosphorylation of three 
proteins with apparent molecular masses of 84, 95, and 97 
kD.  Since  two-dimensional  immunoblot  analysis  has  not 
been performed, the exact number of  phosphoproteins repre- 
sented  by these  three bands  is  unknown.  This pattern  of 
phosphorylation was observed whether platelets were stimu- 
lated in a receptor-mediated fashion by thrombin, collagen, 
or ADP and epinephrine, or in a receptor-independent fash- 
ion by an activator of G proteins (mastoparan) or protein ki- 
nase C (phorbol ester). Using a variety of experimental sys- 
tems and  monitoring techniques,  we established  that this 
pattern of tyrosine phosphorylation is dependent on agonist- 
induced activation of GP Ilb-llIa, fibrinogen binding to GP 
IIb-IIIa, and platelet aggregation. In contrast, platelet ara- 
chidonic acid metabolism, dense granule secretion, and cal- 
pain activity are not necessary for tyrosine phosphorylation 
of these proteins. Table I summarizes the experimental sup- 
port for these conclusions. 
Upon platelet activation, the surface membrane GP nb- 
IIIa  complex undergoes a conformational change that permits 
it to  function  as  a  receptor for adhesive ligands,  includ- 
ing fibrinogen, yon Willebrand factor, and under some cir- 
cumstances,  fibronectin  (Plow  and  Ginsberg,  1989).  In 
plasma, fibrinogen is the dominant ligand (Pietu et al., 1984; 
Gralnick et al.,  1984;  Schullek et al.,  1984).  The binding 
of fibrinogen and RGD-contalning peptides to GP I/b-INa 
has been shown to induce clustering of GP lTo-Ma com- 
plexes within the plane of the plasma membrane (Isenberg 
et al., 1989). In the present study, RGDS binding per se did 
not induce tyrosine phosphorylation in platelets, suggesting 
that clustering of GP lIb-llla complexes is not sufficient to 
induce tyrosine phosphorylation. However, the experiments 
illustrated in Fig. 2 in which agonist-induced tyrosine phos- 
phorylation was  inhibited  by preincubating  platelets  with 
EGTA at 37°C indicated that the functional integrity of GP 
lib-Ilia  is  required  for  these  tyrosine  phosphorylation 
events. 
Fibrinogen binding to activated GP nb-Ma and platelet 
aggregation can be inhibited by RGD-containing peptides, by 
chelation of divalent cations, and by certain anti-GP llb-lIIa 
mAbs (Gartner and Bennett,  1985; Plow et al.,  1985; Ben- 
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which fibrinogen binding and aggregation were inhibited by 
RGDS,  EDTA,  or  mAb  A2A9  (Fig.  3)  suggested  that 
agonist-induced tyrosine phosphorylation required the bind- 
ing of fibrinogen to GP fib-IRa. Although unstirred platelets 
stimulated by agonists displayed evidence of GP fib-IRa acti- 
vation (FITC-PAC1  binding), they did not display the induc- 
ible pattern of tyrosine phosphorylation (Fig. 4), implying 
that platelet aggregation was necessary for these phosphory- 
lation events to occur. Platelet agglutination by ristocetin and 
von Willebrand factor, a process that involves GP Ib and not 
GP fib-IRa, did not induce tyrosine phosphorylation. Thus, 
these studies clearly indicate that GP fib-IRa activation and 
fibrinogen binding are necessary for tyrosine phosphoryla- 
tion, but these events are not sufficient. Rather, once fibrino- 
gen has become bound to activated platelets,  the platelets 
must aggregate in order for the induction of tyrosine phos- 
phorylation to occur. 
We obtained substantial evidence that dense granule secre- 
tion is not required for tyrosine phosphorylation of the 84-, 
95-, and 97-kD proteins and that secretion of dense and alpha 
granules  is not dependent  on tyrosine phosphorylation  of 
these proteins. Pretreatment with aspirin and indomethacin, 
which blocked arachidonic acid metabolism and granule se- 
cretion, did not inhibit the induction of tyrosine phosphory- 
lation by ADP and epinephrine (Fig. 5). In addition, stirred 
platelets underwent full thrombin-induced granule secretion 
under  conditions  where  platelet  aggregation  and  tyrosine 
phosphorylation were blocked by RGDS, EDTA, or the mAb 
A2A9 (Fig. 3). Finally, unstirred platelets exhibited normal 
granule secretion when stimulated with thrombin, but they 
did not aggregate or undergo agonist-induced tyrosine phos- 
phorylation (Fig. 4). It is also likely that tyrosine phosphor- 
ylation is unrelated to agonist-induced platelet shape change, 
the process whereby the cell undergoes spheration and pseu- 
dopodial extension. Unstirred platelets or platelets in EDTA 
can undergo shape change in response to thrombin or ADP 
(Siess, 1989); however, agonist-induced tyrosine phosphory- 
lation was barely detectable under these conditions. 
The observation that fibrinogen binding to GP fib-IRa is 
necessary for the induction of tyrosine phosphorylation  is 
consistent  with  the  recent  findings  of Ferrell  and  Martin 
(1989)  who demonstrated  that  RGDS inhibited  thrombin- 
induced tyrosine phosphorylation of proteins of Mr 126,000, 
108,000 and 100,000, and that these proteins are not phos- 
phorylated in thrombasthenic  platelets which lack GP fib- 
IRa. The antiphosphotyrosine antibodies used in this study 
detected several additional  thrombin-induced  proteins that 
were not sensitive to RGDS, suggesting that all thrombin- 
induced tyrosine phosphorylation events are not dependent 
on fibrinogen binding.  Our results and conclusions differ in 
two respects to those of Ferrell and Martin.  First, although 
Ferrell and Martin observed an induction of tyrosine phos- 
phorylation in response to thrombin, they did not detect such 
phosphorylation when platelets were stimulated with ADP 
in the presence of fibrinogen.  They concluded that ADP- 
induced  activation  of GP  fib-IRa  and  aggregation  were 
insufficient to induce the tyrosine phosphorylation  of pro- 
teins in the 100-kD range. However, we observed that ADP 
or ADP and epinephrine could activate GP fib-IRa and in- 
duce both aggregation and tyrosine phosphorylation. Techni- 
cal considerations may explain this apparent discrepancy. In 
the study of Ferrell and Martin,  platelets were washed by 
repeated centrifugation  rather  than gel filtration.  It is dif- 
ficult to avoid inadvertent platelet activation when platelets 
are  washed by centrifugation.  Platelets  partially  activated 
during the washing process may become relatively refractory 
to subsequent stimulation by agonists (Peerschke, 1985). In- 
deed, Ferrell and Martin did not observe tyrosine phosphor- 
ylation of proteins in the 100-kD range until 3-5 min after 
thrombin stimulation,  while we have observed this pattern 
within 30 s of stimulation  (Golden and Brugge,  1989). 
The second difference between our findings and those of 
Ferreli and Martin is that we found that induction of tyrosine 
phosphorylation was dependent on stirring the suspension of 
activated platelets. We concluded that GP IFo-iRa, fibrino- 
gen  binding  to  GP  fib-IRa,  and  platelet  aggregation  are 
necessary for induction of tyrosine phosphorylation. In con- 
trast, FerreU and Martin concluded that "GP llb-IRa-ligand 
interaction  per se,  and not aggregation",  was required  for 
the induction of tyrosine phosphorylation. Again, technical 
considerations may explain this discrepancy. It is difficult to 
avoid  platelet  microaggregation  when  platelets  are  cen- 
trifuged, washed, and then incubated with thrombin. Indeed, 
we have found that when some degree of tyrosine phosphory- 
lation is observed in a platelet sample believed to contain no 
aggregates,  as  determined  in  a  conventional  platelet  ag- 
gregometer,  microscopic platelet aggregates are invariably 
present. 
What  is  the  exact  relationship  between  tyrosine  phos- 
phorylation  and  platelet  aggregation?  It  is  possible  that 
agonist-induced tyrosine phosphorylation is necessary for an 
event that follows fibrinogen binding to GP fib-IRa and that 
is required  for the process of aggregation.  These "postoc- 
cupancy" events remain  to be characterized,  however, the 
ability of desensitized platelets to bind fibrinogen normally 
(in the absence of aggregating) suggests that fibrinogen bind- 
ing is not sufficient for full platelet aggregation (Peerschke, 
1985;  Shattil  et ai.,  1986).  Alternatively,  tyrosine phos- 
phorylation may be involved in some cellular process that is 
dependent  on  platelet  aggregation  (i.e.,  activation  of the 
Na+/H  * pump).  Although  further  studies will be required 
to establish more precise cause-effect relationships, the pres- 
ent studies clearly establish that induction of tyrosine phos- 
phorylation does not require platelet arachidonic  acid me- 
tabolism or dense granule secretion. In addition, expe  "rnnents 
using the cell permeable calpain inhibitor, E64d, imply that 
tyrosine phosphorylation does not require caipain activation. 
Platelet aggregation  is associated with a structural  reor- 
ganization of the platelet cytoskeleton that is correlated with 
the physical association of GP fib-Ilia  with  one or more 
Triton-insoluble cytoskeletai elements (Phillips et al., 1980). 
Recent studies  suggest that  activated GP fib-iRa may be- 
come associated with a  specific cytoskeletai protein,  talin 
Beckerle et ai.,  1989).  Although the precise role of such 
interactions is speculative, they might be involved in GP fib- 
IRa-mediated adhesion of platelets to the subendothelial ma- 
trix (Weiss et ai.,  1989) or in clot retraction (Cohen et al., 
1989). A direct or indirect association of GP fib-IRa with 
a protein-tyrosine kinase could be one means by which such 
functions are regulated.  In other cells, protein-tyrosine ki- 
nases can induce alterations in the organization of the mem- 
brane  cytoskeleton.  These  kinases  include  the  epidermal 
growth factor receptor (Schlessinger and Geiger, 1981), the 
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Pledger, 1985),  and the viral src (David-Pfeuty and Singer, 
1980), yes (Gentry and Rohrschneider, 1984), abl (Rohrsch- 
neider and Najita,  1984), andfps (Tarone et al., 1985) gene 
products. 
These speculations raise the question as to whether the GP 
Hb-IIIa  complex might  communicate with  a  protein-tyrosine 
kinase. Despite the high levels  of  the  c-src gene product in 
platelets  (0.2% of total  cell  protein [Golden and Brugge, 
1989]),  there  is  as  yet  no  evidence that  this  protein  associates 
with GP IIb-HIa  or  is  the  kinase  responsible  for  the  agonist- 
induced tyrosine  phosphorylation of  the 84-,  95-,  and 97-kD 
proteins (Ferrell  and Martin, 1988; Golden and Brugge, 
1989). Recently,  the CD4 and CD8 receptors  of  helper and 
cytotoxic  T-lymphocytes have been shown to associate  with 
and  regulate  a  src-related  protein-tyrosine  kinase,  p56  ~ 
(Veillette et al.,  1988).  Thus,  the coupling  of cell surface 
receptors  with protein-tyrosine  kinases  could  represent a 
common  mechanism  for  mediating  signal  transduction 
events triggered by cell-cell, and perhaps cell-matrix inter- 
actions. 
The  identifies  of  the  84-,  95-,  and  97-kD  tyrosine- 
phosphorylated proteins in agonist-stirnulated platelets are 
unknown. Although the 95- and 97-kD proteins are similar 
in apparent molecular weight to nonreduced GP HIa, prelim- 
inary immunoblotting and immunoprecipitation studies sug- 
gest that neither of these proteins represents GP llla (Ferrell, 
J., and G. S. Martin, personal communication;  S. Nemeth, 
L. Lipfert, A. Golden, and J. S. Brugge, personal observa- 
tion). Identification of these proteins and their functions will 
be facilitated by their isolation and by analysis of their pri- 
mary structure. 
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